Managing primary central nervous system lymphoma.
Authors: Batchelor T PMID: 26353039 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The effect of cancer treatment on cognitive function.
Authors: Asher A, Myers JS Abstract Cognitive dysfunction is an increasingly recognized complication of cancer and its treatment. Most research in this arena has found that a subset of patients appear to be vulnerable to this complication even after treatment has ended, and often have difficulties with multitasking, short-term memory, word-finding, attention, or concentration. The mechanisms underlying these cognitive changes are not fully elucidated but may include direct neurotoxic effects of therapy, oxidative damage, and genetic predisposition. Compelling evidence has accumulated for the role of immune dysregul...
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?
Authors: Gibney GT, Atkins MB Abstract The recent developments in BRAF-targeted therapy and checkpoint inhibitor immunotherapies for metastatic melanoma patients have led to better tolerability and markedly improved clinical outcomes, including higher objective response rates and longer survival. Treatment planning has become complex in patients with metastatic BRAF-mutant melanoma, with several options for BRAF- and/or MEK-targeted therapy (vemurafenib, dabrafenib, and trametinib) and immunotherapy (interleukin 2, ipilimumab, pembrolizumab, and nivolumab). Clinicians must weigh various patient factors, including t...
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Current and novel treatment options for peripheral T-cell lymphoma.
Authors: Horwitz SM PMID: 26353042 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Frontline management of Hodgkin lymphoma patients with high-risk disease.
Authors: Armitage JO PMID: 26430791 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Treatment of relapsed/refractory Hodgkin lymphoma.
Authors: Chen RW PMID: 26430792 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New frontiers in the management of Hodgkin lymphoma.
Authors: Moskowitz CH PMID: 26430793 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The impact of the AETHERA trial on clinical practice.
Authors: Sweetenham J PMID: 26430794 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Recent considerations in the management of Hodgkin lymphoma: Q&A.
Recent considerations in the management of Hodgkin lymphoma: Q&A. Clin Adv Hematol Oncol. 2015 Feb;13(2 Suppl 1):16-7 Authors: Sweetenham J PMID: 26430795 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Thyroid carcinoma: epidemiology, histology, and diagnosis.
Authors: Shah JP PMID: 26430868 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Local treatment of differentiated thyroid carcinoma.
Authors: Clayman GL PMID: 26430869 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Targeted therapy for advanced or metastatic differentiated thyroid carcinoma.
Authors: Wirth LJ PMID: 26430870 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New and emerging therapeutic options for thyroid carcinoma: q&a discussion.
New and emerging therapeutic options for thyroid carcinoma: q&a discussion. Clin Adv Hematol Oncol. 2015 Apr;13(4 Suppl 4):17 Authors: Clayman GL, Wirth LJ PMID: 26430871 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Gastroenteropancreatic neuroendocrine tumors: diagnosis and classification.
Authors: Kunz PL PMID: 26430956 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Treatment approaches in gastroenteropancreatic neuroendocrine tumors.
Authors: Phan AT PMID: 26430957 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Emerging treatments for gastroenteropancreatic neuroendocrine tumors: use in the clinic.
Authors: Reidy-Lagunes DL PMID: 26430958 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New and emerging treatment options for gastroenteropancreatic neuroendocrine tumors: q&a discussion.
New and emerging treatment options for gastroenteropancreatic neuroendocrine tumors: q&a discussion. Clin Adv Hematol Oncol. 2015 May;13(5 Suppl 5):17 Authors: Phan AT, Kunz PL, Reidy-Lagunes DL PMID: 26430959 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Translating research into practice: the Prosigna® (PAM50) gene signature assay.
Translating research into practice: the Prosigna® (PAM50) gene signature assay. Clin Adv Hematol Oncol. 2015 Jun;13(6 Suppl 6):3-13 Authors: Boccia RV PMID: 26431167 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

A comparison of breast cancer multianalyte assays with algorithmic analyses (MAAA) for their net predictive/prognostic value.
Authors: Dabbs DJ PMID: 26431168 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Genomic signatures in breast cancer: limitations of available predictive data and the importance of prognosis.
Authors: Esteva FJ PMID: 26431169 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Novel management options for adult patients with progressive acute lymphoblastic leukemia: introduction.
Authors: Wang ES PMID: 26431322 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

An ALL patient with a t(4;11) translocation.
Authors: Jabbour EJ PMID: 26431323 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

An ALL patient with heart failure.
Authors: Douer D PMID: 26431324 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Two patients with relapsed/refractory ALL.
Authors: Wang ES PMID: 26431325 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Lanreotide depot/autogel in neuroendocrine tumors: subgroup analyses from the CLARINET study.
Authors: Phan AT PMID: 26431403 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors.
Authors: Phan AT PMID: 26431404 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Lanreotide depot/autogel (LAN) vs. placebo (PBO) for carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs): subgroup analysis of the ELECT study.
Authors: Phan AT PMID: 26431405 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Targeted radionuclide therapy for NETs.
Authors: Phan AT PMID: 26431406 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

SWOG S0518: phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127).
Authors: Phan AT PMID: 26431407 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in GEP-NETs from the 2015 American Society of Clinical Oncology annual meeting: commentary.
Authors: Phan AT PMID: 26431408 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Preliminary efficacy and safety of brentuximab vedotin and AVD chemotherapy followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.
Authors: Moskowitz CH PMID: 26452080 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Response-adapted therapy based on interim FDG-PET scans in advanced Hodgkin lymphoma: first analysis of the safety of deescalation and efficacy of escalation in the international RATHL study (CRUK/07/033).
Authors: Moskowitz CH PMID: 26452081 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Sequential brentuximab vedotin and AVD for older Hodgkin lymphoma patients: initial results from a phase 2 multicenter study.
Authors: Moskowitz CH PMID: 26452082 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Addition of thiotepa and rituximab to antimetabolites significantly improves outcome in primary CNS lymphoma: first randomization of the IELSG32 trial.
Authors: Moskowitz CH PMID: 26452083 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Analysis of primary-refractory Hodgkin lymphoma pts in a randomized, placebo-controlled study of brentuximab vedotin consolidation after autologous stem cell transplant.
Authors: Moskowitz CH PMID: 26452084 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Early FDG-PET adapted treatment improves the outcome of early FDG-PET-positive patients with stages I/II Hodgkin lymphoma (HL): final results of the randomized intergroup EORTC/LYSA/FIL H10 trial.
Authors: Moskowitz CH PMID: 26452085 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Brentuximab vedotin plus AVD for non-bulky limited stage classical Hodgkin lymphoma: a phase 2 trial.
Authors: Moskowitz CH PMID: 26452086 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Rituximab, bendamustine and cytarabine (RBAC500) as induction therapy in elderly patients with mantle cell lymphoma: a phase 2 study from the Fondazione Italiana Linfomi.
Authors: Moskowitz CH PMID: 26452087 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in lymphoma from the 13th International Conference on Malignant Lymphoma: commentary.
Authors: Moskowitz CH PMID: 26452088 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: What I did on my summer vacation.
Authors: Cheson BD PMID: 26452181 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Hem/Onc News.
Authors: Schuyler D PMID: 26452182 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

What is the optimal way to evaluate quality of life in breast cancer trials?
Authors: Ganz PA PMID: 26452183 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
Authors: Venook AP PMID: 26452184 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Contraception in women with hereditary thrombophilic defects.
Contraception in women with hereditary thrombophilic defects. Clin Adv Hematol Oncol. 2015 Sep;13(9):566-8 Authors: Coppens M PMID: 26452185 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The timing of radium-223 therapy in castration-resistant prostate cancer.
Authors: Sartor O PMID: 26452186 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

FLT3 inhibitors for acute myeloid leukemia.
Authors: Lancet JE PMID: 26452187 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The time for molecular phenotyping of metastatic castrate-resistant prostate cancer is now.
Authors: VanderWeele DJ PMID: 26452188 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

There is no current role for molecular phenotyping in metastatic castrate-resistant prostate cancer.
Authors: Vogelzang NJ PMID: 26452189 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New insights into hematopoietic stem cell transplantation for chronic lymphocytic leukemia: a 2015 perspective.
Authors: McClanahan F, Gribben J Abstract A considerable body of evidence demonstrates that allogeneic hematopoietic stem cell transplantation (HSCT) offers the only potentially curative treatment option for patients with chronic lymphocytic leukemia (CLL). However, this approach is suitable for only a minority of CLL patients, owing to its significant treatment-related mortality and morbidity. Until recently, internationally accepted guidelines suggested that HSCT should be considered in physically fit CLL patients who carry poor-risk features, such as TP53 abnormalities, or who had a short response to previous im...
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Monoclonal antibodies in myeloma.
Authors: Sondergeld P, van de Donk NW, Richardson PG, Plesner T Abstract The development of monoclonal antibodies (mAbs) for the treatment of disease goes back to the vision of Paul Ehrlich in the late 19th century; however, the first successful treatment with a mAb was not until 1982, in a lymphoma patient. In multiple myeloma, mAbs are a very recent and exciting addition to the therapeutic armamentarium. The incorporation of mAbs into current treatment strategies is hoped to enable more effective and targeted treatment, resulting in improved outcomes for patients. A number of targets have been identified, includi...
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research